Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UDY6
UPID:
TRI10_HUMAN
Alternative names:
B30-RING finger protein; RING finger protein 9
Alternative UPACC:
Q9UDY6; A6NF84; Q5SRJ5; Q5SRK8; Q86Z08; Q96QB6; Q9C023; Q9C024
Background:
Tripartite motif-containing protein 10, also known as B30-RING finger protein or RING finger protein 9, plays a pivotal role in erythroid cell differentiation and survival. It may enhance PTEN ubiquitination, leading to proteasomal degradation and activation of hypertrophic signaling. Beyond its E3 ligase activity, it regulates the immune response by repressing STAT1 and STAT2 phosphorylation in the interferon/JAK/STAT pathway, through interaction with IFNAR1, inhibiting TYK2 and IFNAR1 association.
Therapeutic significance:
Understanding the role of Tripartite motif-containing protein 10 could open doors to potential therapeutic strategies.